49.23
price down icon0.26%   -0.13
pre-market  시장 영업 전:  49.00   -0.23   -0.47%
loading

Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스

pulisher
08:25 AM

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

08:25 AM
pulisher
07:40 AM

Goldman Sachs holds neutral on Bristol-Myers with $55 target - Investing.com

07:40 AM
pulisher
Apr 19, 2025

Bristol-Myers Squibb (BMY) Shares Decline Amid FDA Updates and Mixed Trial Results - GuruFocus

Apr 19, 2025
pulisher
Apr 18, 2025

Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

Bristol-Myers Squibb (NYSE:BMY) Gains FDA Approval To Simplify Camzyos Monitoring Process - Yahoo

Apr 18, 2025
pulisher
Apr 18, 2025

Bristol Myers (BMY) Gains FDA Nod for Updated Camzyos Label to Simplify Treatment | BMY Stock News - GuruFocus

Apr 18, 2025
pulisher
Apr 17, 2025

Hold Rating on Bristol-Myers Squibb Amid Revenue Challenges and Sector-Wide Valuation Pressures - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Apr 17, 2025
pulisher
Apr 17, 2025

Bristol Myers (BMY) Target Price Trimmed as Revenue Projections Dip | BMY Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 16, 2025

Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now? - Insider Monkey

Apr 16, 2025
pulisher
Apr 16, 2025

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Gilead Vs Bristol Myers: Which Biotech Bigwig Is A Better Bet Now? - Barchart.com

Apr 16, 2025
pulisher
Apr 16, 2025

Bristol-Myers Squibb (BMY): Potential 19.73% Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews

Apr 16, 2025
pulisher
Apr 15, 2025

Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Ca - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Cancer Diagnosis - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol Myers' heart disease drug fails to meet main goals in late-stage study - Reuters

Apr 15, 2025
pulisher
Apr 15, 2025

Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol Myers Squibb (BMY) Sees Stock Dip as Camzyos Trial Falls Short - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol Myers stumbles in bid to widen heart drug’s use - BioPharma Dive

Apr 15, 2025
pulisher
Apr 15, 2025

BMO maintains Bristol-Myers $61 target after trial setback - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

BMO maintains Bristol-Myers $61 target after trial setback By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol-Myers stock dips on trial results - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

BMS’ Camzyos fails to show new cardiomyopathy benefit in Phase III - PharmaLive

Apr 15, 2025
pulisher
Apr 15, 2025

OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra - 01net

Apr 15, 2025
pulisher
Apr 15, 2025

Optellum announces agreement with Bristol Myers Squibb to leverage AI to boost early lung cancer diagnosis - Health Tech World

Apr 15, 2025
pulisher
Apr 15, 2025

BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis - Quantisnow

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires? - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool

Apr 15, 2025
pulisher
Apr 15, 2025

BMS Phase III Camzyos trial misses endpoints - The Pharma Letter

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol-Myers Squibb: Hold Rating Amid Mixed Financial Signals and Future Prospects - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Chemotherapy Market Overall Study Report 2025-2032 | - openPR.com

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol Myers (BMY) Reports Unmet Goals in Key Trial for Camzyos - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey

Apr 15, 2025
pulisher
Apr 14, 2025

Bristol Myers falls as heart disease drug fails in late-stage trial - TradingView

Apr 14, 2025
pulisher
Apr 14, 2025

Bristol Myers reports setback in Camzyos heart drug trial - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

HDAC Inhibitors Market Projected to Grow Significantly Through 2034 | DelveInsight - The Globe and Mail

Apr 14, 2025
pulisher
Apr 14, 2025

BMS’ Opdivo combo approved in US for hepatocellular carcinoma - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

Bristol Myers: new approval for Opdivo+Yervoy - marketscreener.com

Apr 14, 2025
pulisher
Apr 13, 2025

BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week - MedCity News

Apr 13, 2025
pulisher
Apr 13, 2025

Pomalyst monopoly case: Bristol Myers wins dismissal of lawsuit - Medical Dialogues

Apr 13, 2025
pulisher
Apr 12, 2025

Bristol Myers Squibb (BMY) Secures FDA Approval for Liver Cancer Treatment - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

UBS cuts Bristol-Myers Squibb price target to $54 from $60 By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods - insights.citeline.com

Apr 11, 2025
pulisher
Apr 11, 2025

Bristol-Myers Squibb Faces Q1 Expectations With Eliquis And Revlimid Leading - Finimize

Apr 11, 2025
pulisher
Apr 11, 2025

Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires? - Insider Monkey

Apr 11, 2025
pulisher
Apr 11, 2025

Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer - Fierce Pharma

Apr 11, 2025
pulisher
Apr 11, 2025

UBS cuts Bristol-Myers Squibb price target to $54 from $60 - Investing.com Australia

Apr 11, 2025
pulisher
Apr 11, 2025

Here's What to Expect From Bristol-Myers Squibb's Next Earnings Report - TradingView

Apr 11, 2025
pulisher
Apr 11, 2025

Here's What To Expect From Bristol-Myers Squibb's Next Earnings Report - Barchart.com

Apr 11, 2025
pulisher
Apr 11, 2025

Dasatinib Drugs Market Deep Research 2025-2032 | Bristol-Myers - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga

Apr 11, 2025
drug_manufacturers_general PFE
$22.14
price up icon 0.45%
drug_manufacturers_general SNY
$50.90
price up icon 0.67%
$104.54
price down icon 0.32%
$277.29
price down icon 1.89%
drug_manufacturers_general MRK
$78.00
price up icon 2.01%
drug_manufacturers_general NVS
$110.86
price up icon 1.17%
자본화:     |  볼륨(24시간):